Journal
BLOOD
Volume 121, Issue 17, Pages 3493-3501Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-11-466227
Keywords
-
Categories
Funding
- National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01 DK29902, F31 DK094650]
- Virginia Commonwealth University Massey Cancer Center National Cancer Institute (NCI) [P30CA16059]
Ask authors/readers for more resources
An understanding of the human fetal to adult hemoglobin switch offers the potential to ameliorate beta-type globin gene disorders such as sickle cell anemia and beta-thalassemia through activation of the fetal gamma-globin gene. Chromatin modifying complexes, including MBD2-NuRD and GATA-1/FOG-1/NuRD, play a role in gamma-globin gene silencing, and Mi2 beta (CHD4) is a critical component of NuRD complexes. We observed that knockdown of Mi2 beta relieves gamma-globin gene silencing in beta-YAC transgenic murine chemical inducer of dimerization hematopoietic cells and in CD34(+) progenitor-derived human primary adult erythroid cells. We show that independent of MBD2-NuRD and GATA-1/FOG-1/NuRD, Mi2 beta binds directly to and positively regulates both the KLF1 and BCL11A genes, which encode transcription factors critical for gamma-globin gene silencing during beta-type globin gene switching. Remarkably, <50% knockdown of Mi2 beta is sufficient to significantly induce gamma-globin gene expression without disrupting erythroid differentiation of primary human CD34(+) progenitors. These results indicate that Mi2 beta is a potential target for therapeutic induction of fetal hemoglobin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available